Digital Health Coffee Time Briefing ☕

Your morning summary of digital health news, information and events to know about if you want to be “in the know”.

👇 News

🧠 Kooth, a provider of digital mental health services, announced the acquisition of US paediatric digital health company Kismet Health’s telehealth platform. The platform has been designed with interactive and age-appropriate tools to enhance engagement during teletherapy, principally for children aged 5-12.

👨‍💻A study published in the Journal of Clinical Oncology has shown that C the Signs, an AI platform supporting earlier cancer diagnosis, has delivered an 808% return on investment for the NHS. The independent evaluation commissioned by Health Innovation East, found that the platform’s across Suffolk and North East Essex Integrated Care Board was associated with 272 patients being diagnosed earlier and £1.5 million in annual cost savings.

🤝Hyland and Tribun Health have joined forces to advance pathology workflows by integrating Tribun Health’s platform with Hyland’s enterprise imaging solutions. The system aggregates and archives digital pathology gross images and whole slide images alongside radiology, cardiology, and other imaging specialties, providing clinicians with a single view of each patient’s complete imaging record.

💵University of Gloucestershire has been awarded £2.5m by the Office for Students to open FutureSim – an AI-powered Centre of Excellence for Simulation and Technology-Enhanced Immersive Learning. FutureSim will bring together and expand the university’s existing simulation facilities into one integrated hub, featuring five modular zones designed to replicate real-world environments including clinical, community, forensic, custodial, and outdoor settings.

💊Cellbyte, an AI-native platform for pharmaceutical companies, has raised $2.75 million in seed funding. Cellbyte has developed a platform for teams involved in drug launches, which allows them to analyse millions of data points in real time across clinical, pricing, HTA, and regulatory data, as well as internal company sources.

❓ Did you know that?

RadNet, a US provider of outpatient diagnostic imaging services, and its subsidiary DeepHealth have announced results from a real-world analysis of AI-driven breast cancer screening conducted in the US.

Published in Nature Health, on 17 November 2025, the findings support the clinical effectiveness and benefit of DeepHealth’s AI technology to deliver equitable results across several racial, ethnic, and breast density patient groups.

“Beyond the remarkable results, what sets this research apart is its scale, diversity and real-world applicability,” said Dr Howard Berger, president and chief executive officer of RadNet.

“There has never been a similar study of this size in the United States, much less one with such a diverse patient population, that examines the patient impact and efficacy of AI-assisted breast cancer screening.”

📖 What we’re reading

The European Society for Medical Oncology has published the first global guidance on validation requirements for AI-based biomarkers in cancer care. This landmark framework, called EBAI, sets clear rules for developers, clinicians, and regulators to standardise how AI-based biomarkers are integrated into oncology.

The guidance delves into the ways AI is contributing to decision-making. These systems, the authors write, can predict treatment responses and clinical outcomes, sometimes spotting patterns invisible to humans.

The project is the start of a long-term effort whereby ESMO is building a suite of frameworks to guide the responsible use of AI in cancer care, shaping regulatory discussions and clinical practice worldwide.

🚨 Upcoming events

12 December 2025, Online – Allied Health Professionals and the Digital Commitments of the 10 Year Plan